Shots:

• The P-III CheckMate -214 trial evaluates Opdivo (3mg/kg) + Yervoy (1mg/kg- q3w for 4 doses) vs sunitinib in 1096 patients with previously untreated advanced/mRCC
• Results: @median follow-up of 67.7mos.- combination showed superior OS in intermediate- poor risk patients & randomized or ITT population; m-OS (47.0 vs 26.6mos.) & (55.7 vs 38.4mos.); ORR (42% vs 27%) & (39% vs 32%); DoR (not reached in all population vs 19.7 & 24.8mos.); CR rate (11% vs 2%) & (12% vs 3%); OS rates @ 5yrs. (43% and 31%) & (48% and 37%) respectively
• Patients were alive (81% vs 72%)- PFS (89% vs 57%)- patients responded (89% vs 63%) @5yrs.- safety profile was manageable & no new safety signals were observed

  Ref: BMS | Image: BMS